Treatment of Eosinophilic Fasciitis With Sirolimus | Dermatology | JAMA Dermatology | JAMA Network
[Skip to Navigation]
Sign In
April 2016

Treatment of Eosinophilic Fasciitis With Sirolimus

Author Affiliations
  • 1Department of Dermatology, New York University School of Medicine, New York
  • 2Department of Dermatology, University of California, San Francisco
  • 3Department of Dermatology, Palo Alto Foundation Medical Group, Mountain View, California
JAMA Dermatol. 2016;152(4):488-490. doi:10.1001/jamadermatol.2016.0048

Eosinophilic fasciitis (EF) is a disorder in which the subcutaneous tissues become indurated and then sclerotic leading to myalgia, arthralgia, and occasionally contractures and disability. High-dose systemic steroids are first-line therapy; however, steroid-sparing agents are often used owing to disease progression or to avoid the adverse effects of long-term corticosteroid use. We describe a case of EF with rapid response to sirolimus.

Report of a Case

A man in his 30s had a 6-month history of arthralgia involving his shoulders, hands, knees, ankles, and feet, which made it difficult for him to stand or walk for long periods. He complained of swelling and “skin tightness” of his arms, lower legs, and hands. On examination, he had woody induration of his distal extremities creating both peau d’orange surface change and linear depressions along the veins of his right forearm consistent with a groove sign. His fingers were held in a slight flexion contracture at the proximal interphalangeal joints (Figure, A).

Figure.  Clinical Images Taken Before and After 2 Months of Sirolimus Therapy
Clinical Images Taken Before and After 2 Months of Sirolimus Therapy

A, Induration and skin tightness causes discomfort and inability to make a fist. B, Much improved finger mobility allows the patient to make a fist after 2 months of sirolimus therapy.

Laboratory tests revealed a transient eosinophilia (total eosinophil count, 600/μL), polyclonal hypergammaglobulinemia, a mildly elevated erythrocyte sedimentation rate (22 mm/h), and negative results for antinuclear antibodies and anti-U1RNP and anti-Scl-70 antibodies. He lacked features of systemic sclerosis, including Raynaud phenomenon, sclerodactyly, or nail fold capillary changes. An incisional biopsy of his calf extending into the deep subcutaneous fat, but not including fascia, revealed thickening of the subcutaneous septae with edema and a lymphoplasmacytic infiltrate with eosinophils. The histopathologic findings was most compatible with a deep sclerosing process such as morphea profunda or EF. Given his cutaneous findings and histopathologic deep sclerosis, he was diagnosed with EF.

The patient was treated with physical therapy, low-dose prednisone, and methotrexate, 25 mg/wk, for 4 months without an improvement in induration or pain. His prednisone dose ranged between 5 and 20 mg/d for 7 months (the patient had concerns about the adverse effects of high-dose steroids). Given the progressive sclerosis, methotrexate treatment was stopped; prednisone regimen was continued at 5 mg/d; and sirolimus therapy was started at 2 mg/d. Within 6 weeks, there was a reduction of pain and skin thickening (Figure, B). Nine months into therapy, the patient remained on the regimen of sirolimus, 2 mg/d, and prednisone, 5 mg/d. He experienced occasional hand arthralgia but regained the ability to walk long distances, exercise in the gym, and make a fist. The sirolimus regimen will be tapered once his clinical symptoms have completely resolved.


Mechanistic target of rapamycin (mTOR) is a cell-signaling serine–threonine kinase that exists as 2 distinct complexes, mTORC1 and mTORC2. Sirolimus predominately inhibits mTORC1 and is commonly used to prevent graft rejection in transplant patients. Sirolimus has been shown to decrease the development of fibrosis in transplanted donor organs in both animal models and clinical studies.1 The mTOR complexes are one of the downstream signals of transforming growth factor (TGF)-β, a key regulator of fibrosis, and inhibition of mTOR is believed to decrease fibroblast function, collagen deposition, and epithelial to mesenchymal transition, a process important in generating fibroblasts and myofibroblasts.2 Sirolimus has led to improvement in cases of nephrogenic systemic fibrosis and modest improvement in systemic sclerosis.3,4 Recently, a dual inhibitor of mTOR complexes 1 and 2 has been shown to reverse TGF-β–induced fibrosis by dermal fibroblasts.5

Eosinophilic fasciitis is a sclerosing disorder for which both high-dose corticosteroids and methotrexate treatments are frequently used, but a complete response is seen in only two-thirds of cases.6

Based on this case report, sirolimus holds potential as an alternative therapy for EF. Further research on mTOR and the development of newer mTOR inhibitors could provide future therapies for other difficult-to-treat sclerosing skin disorders.

Back to top
Article Information

Corresponding Author: Jenny E. Murase, MD, Department of Dermatology, Palo Alto Foundation Medical Group, 701 E El Camino Real (31-104), Mountain View, CA 94040 (

Published Online: March 2, 2016. doi:10.1001/jamadermatol.2016.0048.

Conflict of Interest Disclosures: None reported.

Kelly  MA, Kaplan  M, Nydam  T,  et al.  Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience.  Transplant Proc. 2013;45(9):3325-3328.PubMedGoogle ScholarCrossref
Lamouille  S, Derynck  R.  Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.  J Cell Biol. 2007;178(3):437-451.PubMedGoogle ScholarCrossref
Swaminathan  S, Arbiser  JL, Hiatt  KM,  et al.  Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase.  J Am Acad Dermatol. 2010;62(2):343-345.PubMedGoogle ScholarCrossref
Su  T-IK, Khanna  D, Furst  DE,  et al.  Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study.  Arthritis Rheum. 2009;60(12):3821-3830.PubMedGoogle ScholarCrossref
Mitra  A, Luna  JI, Marusina  AI,  et al.  Dual mTOR inhibition is required to prevent TGF-β-mediated fibrosis: implications for scleroderma.  J Invest Dermatol. 2015;135(11):2873-2876.PubMedGoogle ScholarCrossref
Wright  NA, Mazori  DR, Patel  M, Merola  JF, Femia  AN, Vleugels  RA.  Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers.  JAMA Dermatol. 2016;152(1):97-99.PubMedGoogle ScholarCrossref